Form 4: Stoke Therapeutics Executive Jonathan Allan Reports Stock Sales and Option Grant

Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, reports sales of common stock to cover tax obligations and the grant of stock options and restricted stock units.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 18, 2025, Allan sold 2,266 shares of common stock at a weighted average price of $8.67 per share, with prices ranging from $8.11 to $8.925.
• On March 19, 2025, Allan sold 1,945 shares of common stock at a weighted average price of $8.27 per share, with prices ranging from $8.06 to $8.95.
• These sales were mandated by the issuer to cover tax withholding liabilities related to the vesting of restricted stock units.
• Allan was also granted an option to purchase 72,000 shares of common stock at an exercise price of $8.33 on March 20, 2025, which vests monthly starting April 15, 2025, and expires on March 19, 2035.
• Additionally, Allan received 48,000 restricted stock units on March 20, 2025, which vest annually beginning on March 15, 2026.
• Following these transactions, Allan directly owns 31,565 shares of common stock, 72,000 stock options, and 48,000 restricted stock units.

Sentiment

Score: 6

Explanation: The document is neutral. It reports routine transactions. The stock sales are for tax purposes, and the grants are part of standard compensation.

Positives

• The grant of stock options and restricted stock units aligns Allan's interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize continued service to the company.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although it is a common practice.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Stoke Therapeutics' stock price.
• Changes in tax laws could affect the tax liabilities associated with the vesting of restricted stock units.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules suggest an expectation of continued employment and company growth.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain talent.
• Vesting schedules are generally structured to align employee incentives with long-term company performance, similar to practices at companies like Vertex Pharmaceuticals and Biogen.

Stakeholder Impact

• Shareholders may view the insider transactions as a reflection of management's confidence (or lack thereof) in the company.
• Employees may be affected by the vesting of their own stock options and restricted stock units.

Key Dates

Keywords

Form 4, Stoke Therapeutics, STOK, Jonathan Allan, stock options, restricted stock units, insider trading, beneficial ownership, stock sale